A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis

NCT04090411 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

246

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Ulcerative Colitis

Interventions

DRUG: Induction- PF-06480605 50 mg SC Q4W
DRUG: Induction- PF-06480605 150 mg SC Q4W
DRUG: Induction- PF-06480605 450 mg SC Q4W
OTHER: Induction- Placebo SC Q4W
DRUG: Chronic- PF-06480605 50 mg SC Q4W
DRUG: Chronic- PF-06480605 150 mg SC Q4W
DRUG: Chronic- PF-06480605 450 mg SC Q4W

Sponsor

Hoffmann-La Roche

Collaborators

[object Object]